Pfizer CEO and leadership

Albert Bourla (Greek: Άλμπερτ Μπουρλά, born) is a Greek veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.

Mikael Dolsten (born c. 1958) is a Swedish-American physician scientist , and the President of research & development-Medical (chief scientific officer) of the American Pharmaceutical company Pfizer.

Lidia Fonseca is Executive Vice President, Chief Digital and Technology Officer at Pfizer, responsible for developing and implementing an enterprise-wide digital strategy. Lidia leads all digital, data and technology solutions across the company.

She spearheads several transformational programs and initiatives to support Pfizer’s purpose of delivering Breakthroughs that Change Patients’ Lives applying digital capabilities and products including: digitizing drug discovery and development; improving health outcomes and patient experiences; improving operational processes through automation and robotics; and delivering powerful insights with advanced data and analytics for better decision-making.

Lidia leads the effort to create Pfizer’s Advanced Analytics Platform that brings together data from Pfizer and external partners as well as tools to model scientific and clinical decisions, patterns and insights. She is also driving initiatives to re-imagine clinical trials through robotics/automation and tech-enabled processes that enhance patient, provider and site experiences, improve selection and recruitment, and reduce clinical trial cycle times.

Lidia led the effort to launch Pfizer’s Digital Companion™, a suite of digital products and solutions for every therapy to deepen engagement between patients and physicians for better outcomes. She recently collaborated to deliver five Pfizer Digital Companions™: Mabu Wellness Coach for patients, Champix Chatbot to assist with smoking cessation, LivingWith app to support patients, and their loved ones, undergoing cancer treatment, drone medicine delivery in the Dominican Republic to increase patient access to medicines in remote and difficult-to-reach locations, and a partnership with Fitbit to drive timely diagnosis of atrial fibrillation.

She also leads initiatives to empower Pfizer colleagues, simplifying and automating their work with robotics, machine learning, and predictive analytics that enable better and faster decisions, while driving efficiencies. In 2019, Pfizer automated 30 percent of approximately 100 million transactions across the company.

In her prior role, Lidia was the Senior Vice President and CIO at Quest Diagnostics, the world’s leading provider of diagnostic information services serving one in three American adults each year, and half the physicians and hospitals in the U.S. She was responsible for technology, informatics and digital solutions. Lidia led the effort to create Quest's innovative Quanum Solutions brand of healthcare IT and data analytics offerings that deliver critical insights to improve quality outcomes and patient care while lowering costs.

Lidia was named a Healthcare Transformer by Medical, Marketing & Media in 2019. In 2018, she was the only diagnostics provider executive to participate in the White House Artificial Intelligence Summit. She received the 2017 Forbes CIO Innovation Award that recognizes CIOs who lead revenue enhancing innovation efforts. Lidia was a founding member of Synaptic Health Alliance, that includes leading healthcare companies Aetna, Ascension Health, Humana, MultiPlan, Optum, Quest Diagnostics and United Health Group, using blockchain technology to improve provider data quality, which will serve as a new distributed partnership model that can be used to tackle other industry-wide data issues.

Lidia is a member of the Board of Directors of Tegna, Inc. (NYSE: TGNA). She also was a board member of Q2 Solutions, a joint venture between Quest Diagnostics and IQVIA from 2016 to 2018. She earned a bachelor’s degree from the University of California, Berkeley and an MBA and Master Business Informatics from Rotterdam School of Management, Erasmus Graduate School of Business. Lidia is married and has two children.

Albert Bourla (Greek: Άλμπερτ Μπουρλά, born) is a Greek veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.

Frank D’Amelio is the Chief Financial Officer and Executive Vice President Business Operations & Global Supply, responsible for finance, supply chain, procurement and real estate. Frank led the acquisition and integration of Medivation, Inc., Anacor Pharmaceuticals, Inc., Hospira Inc., and Wyeth Pharmaceuticals, as well as the spin-off of Pfizer’s animal health business, Zoetis, and the sale of its nutrition business to Nestle and its Capsugel business to KKR.

Before joining the company in September 2007, he was Senior Executive Vice President of Integration and Chief Administrative Officer of Alcatel-Lucent, responsible for the integration of the Alcatel-Lucent merger as well as procurement, real estate, IT and supply chain.

Prior to the merger of Alcatel and Lucent Technologies in 2006, Frank was the Chief Operating Officer of Lucent Technologies. In 2001, he was appointed Executive Vice President and Chief Financial Officer of Lucent, where he helped lead the company through one of the most challenging periods in the telecom industry’s history and returned the company to profitability.

When Lucent was spun off from AT&T in 1996, Frank helped create the new company financially as the CFO of Lucent’s Network Systems Business and was a critical member of the team that met with investors around the world during Lucent’s initial public offering. In 1999, he was appointed the Group President of Lucent’s Switching Solutions Business Unit, where he led Lucent’s multibillion-dollar, global Switching, Access and Application Software businesses.

Born and raised in New Jersey, Frank earned his MBA in Finance from St. John’s University and his bachelor’s degree in Accounting from St. Peter’s University. He started his career in 1979 at Bell Labs, holding a variety of financial, accounting and general management positions, and moved within AT&T, holding a series of positions with increasing responsibility.

In 2005, 2006, 2011, 2012, 2013, 2014, 2016 2017, 2018 and 2019, Frank was ranked among America’s top CFOs by Institutional Investor magazine. In 2002, he was recognized by Treasury & Risk Magazine as one of America’s Top CFOs.

He currently serves on the Board of Directors of: Humana, Inc. and is chair of the Audit Committee; Zoetis, Inc.; and the Independent College Fund of New Jersey.